Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04821284 · ClinicalTrials.gov registry record · Phase 1

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

A Phase 1 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, sponsored by Flemming Forsberg.

Active
Registry status
Phase 1
Development phase
120
Enrollment target
2
Study locations

NCT04821284 is a Phase 1 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8 that is active but no longer recruiting, run by Flemming Forsberg. The registered enrollment target is 120 participants, above the 85-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (41% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04821284, a Phase 1 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, is active but no longer recruiting, sponsored by Flemming Forsberg.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
2
Study locations

Study Summary

This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer. Sonoporation is a novel method that uses ultrasound and microbubbles to increase therapeutic effect by increasing uptake or enhance sensitization. Sonoporation together with chemotherapy may work better in treating patients with pancreatic cancer compared to chemotherapy alone.

Conditions Studied

Stage IV Pancreatic Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Metastatic Pancreatic Ductal Adenocarcinoma Stage II Pancreatic Cancer AJCC v8 Locally Advanced Pancreatic Ductal Adenocarcinoma Stage IIA Pancreatic Cancer AJCC v8 Stage IIB Pancreatic Cancer AJCC v8 Unresectable Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG Fluorouracil
  • DRUG Nab-paclitaxel
  • DRUG Irinotecan Hydrochloride
  • DRUG Gemcitabine Hydrochloride
  • DRUG Leucovorin Calcium

Study Locations (2)

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Other

  • Haukeland University Hospital - Bergen

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2021-12-06
Est. Completion 2026-02-28
Phase Phase 1

Sponsor

Flemming Forsberg

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04821284

The ClinicalTrials.gov registry entry for NCT04821284 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (41% higher). The listed sponsor is Flemming Forsberg, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Stage IV Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.

NCT04821284 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Other.

Frequently Asked Questions

What is clinical trial NCT04821284 about?

NCT04821284 is a clinical study titled "Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer". This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer. Sonoporation is a novel method that uses ultrasound and microbubbles to increase therapeutic effect by increasing uptake or enhance sensitization. Sonopo...

What is the current status of trial NCT04821284?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2021-12-06. Estimated completion is 2026-02-28.

What conditions does trial NCT04821284 study?

This clinical trial studies the following conditions: Stage IV Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Locally Advanced Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT04821284?

The interventions under investigation include: Fluorouracil (DRUG), Nab-paclitaxel (DRUG), Irinotecan Hydrochloride (DRUG), Gemcitabine Hydrochloride (DRUG), Leucovorin Calcium (DRUG).

Who is sponsoring clinical trial NCT04821284?

This trial is sponsored by Flemming Forsberg, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04821284 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Pancreatic Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Pancreatic Cancer AJCC v8

All registered trials for this condition

Stage III Pancreatic Cancer AJCC v8

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.